Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/02/02 23:14:55」(JST)
wiki en
English Journal
- [Brain metastasis in breast cancer].
- Korytova LI, Meshechkin AV, Zhabuna RM, Masliukova EA, Ivanov VG.AbstractBrain metastasis is an important issue in modern neurooncology. Our results of combined treatment of brain metastases are presented and available approaches to brain irradiation and chemotherapy are discussed. There is strong evidence to suggest that maximum combinations of approaches might improve treatment efficacy and extend median overall survival to as long as 6 months (p < or = 0.05).
- Voprosy onkologii.Vopr Onkol.2011;57(5):672-4.
- Brain metastasis is an important issue in modern neurooncology. Our results of combined treatment of brain metastases are presented and available approaches to brain irradiation and chemotherapy are discussed. There is strong evidence to suggest that maximum combinations of approaches might improve
- PMID 22238942
- Antibody therapy for rheumatoid arthritis.
- Taylor PC.SourceThe Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, 1 Aspenlea Road, London W6 8LH, UK. peter.c.taylor@ic.ac.uk
- Current opinion in pharmacology.Curr Opin Pharmacol.2003 Jun;3(3):323-8.
- High-quality monoclonal antibodies (mAbs) with specificity for relevant disease molecules can now be produced in abundance. Anti-tumour necrosis factor-alpha therapies have set a new standard for symptom control in rheumatoid arthritis, and blockade of tumour necrosis factor has the potential to pro
- PMID 12810200
- Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.
- Hepburn TW, Totoritis MC, Davis CB.SourceDrug Metabolism and Pharmacokinetics, GlaxoSmithKline, 709 Swedeland Road, PO Box 1539 (UW2720), King of Prussia, PA 19406, USA. timothy_w_hepburn@gsk.com
- Rheumatology (Oxford, England).Rheumatology (Oxford).2003 Jan;42(1):54-61.
- OBJECTIVE: Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Clenoliximab, an immunoglobulin G4 derivative of keliximab, has substantially reduced potential to deplete CD4 cells. In in
- PMID 12509613
Japanese Journal
- Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma
- KON OM.
- Lancet 352, 1109-1113, 1998
- NAID 30005707590
Related Links
- Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
- Hum Exp Toxicol. 2000 Apr;19(4):230-43. Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Bugelski PJ, Herzyk DJ, Rehm S , ...
Related Pictures
★リンクテーブル★
| リンク元 | 「mab」 |
「mab」
mab
- abciximab
- adahmumab
- adalimumab
- afelimomab
- alemtuzumab
- apolizumab
- arcitumomab
- basiliximab
- bevacizumab
- cantuzumab
- certolizumab
- cetolizumab
- cetuximab
- clenoliximab
- daclizumab
- デノスマブ denosumab 抗RANKL抗体
- eculizumab
- edrecolomab
- efalizumab
- epratuzumab
- galiximab
- gemtuzumab
- ibritumomab
- インフリキシマブ infliximab 抗TNF-α抗体 クローン病 Ph+ALL
- inotuzumab
- keliximab
- natalizumab
- nebacumab
- omalilzumab
- omalizumab
- oregovomab
- palivizumab
- panitumumab
- pertuzumab
- pexelizumab
- リツキシマブ rituximab：抗CD20抗体：慢性リンパ性白血病、B細胞リンパ腫